NextCure, Inc. (NXTC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients. This report covers the quarterly period ended September 30, 2025. The company operates as a non-accelerated filer and smaller reporting company. On July 14, 2025, the company effectuated a 1-for-12 reverse stock split; all share data presented has been adjusted retrospectively.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8.6) million | $(11.5) million | $(46.4) million | $(44.1) million |
| Loss Per Share (Basic/Diluted) | $(3.22) | $(4.95) | $(18.84) | $(18.91) |
| Operating Expenses | $8.9 million | $12.5 million | $47.9 million | $47.3 million |
| Cash & Marketable Securities | $29.1 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $426.5 million (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | N/A | $(42.0) million | $(33.8) million |
Material Changes vs. Prior Period
- Expense Reduction: Operating expenses decreased by $3.6 million in Q3 2025 compared to Q3 2024, driven by lower personnel costs (including stock-based compensation) and reduced spending on deprioritized programs (NC410 and NC525).
- License Agreement Impact: YTD 2025 R&D expenses increased by $5.5 million compared to YTD 2024. This increase is primarily due to a $17.0 million upfront payment and related costs associated with a new License Agreement signed in June 2025 with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. for the ADC candidate SIM0505.
- Restructuring: No restructuring or asset impairment charges were recorded in 2025, compared to $2.5 million in charges during the same period in 2024.
- Capital Structure: The company issued 338,636 shares in a private placement to Simcere Zaiming in June 2025 for $2.0 million. These shares were initially classified as mezzanine equity and reclassified to permanent equity in July 2025 upon SEC registration effectiveness.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year following the issuance of these financial statements. Current cash and marketable securities ($29.1 million) are insufficient to fund operations beyond mid-2026 without additional financing.
- Capital Needs: The company intends to raise additional capital through equity offerings, debt financing, or strategic partnerships. Failure to secure funding may force the company to delay, limit, or terminate clinical programs and implement further cost-cutting measures.
- Clinical Progress:
- SIM0505: First patient dosed in October 2025; proof of concept data expected in H1 2026.
- LNCB74: Phase 1 trial ongoing; FDA cleared protocol amendment for higher dose cohorts in November 2025; proof of concept data expected in H1 2026.
- Unusual Items: The $17 million license fee for SIM0505 was expensed immediately as in-process research and development (IPRD) with no alternative future use. A $1.5 million milestone payment to Zaiming was triggered in October 2025 upon Phase 1 initiation.
Investor Verification Checklist
- Verify the timeline and terms of the upcoming capital raise required to address the "substantial doubt" going concern warning.
- Confirm the status of the $1.5 million milestone payment obligation to Zaiming triggered in October 2025.
- Monitor the progress of the SIM0505 and LNCB74 Phase 1 trials, specifically the anticipated H1 2026 data readouts.
- Review the impact of the 1-for-12 reverse stock split on share liquidity and market price.
- Assess the company's ability to secure partnerships for deprioritized programs (NC410, NC525) to offset R&D costs.